AbCellera Biologics Inc. - Q3 2026 Earnings Results and Business Update - ABCELLERA BIOLOGICS INC

Financial Performance:

• Reported Q3 2026 revenue of >$10 million, up from ~$9 million in Q3 2025, driven primarily by research fees from strategic deals.
• Net loss for the quarter was ~$41 million ($0.13 EPS), a reduction from $57 million in the prior year period.
• R&D expenses were ~$44 million (up due to internal program investments), while SG&A decreased to ~$14 million (down from $25 million last year) following the conclusion of IP litigation and team restructuring.
• Company holds >$790 million in cash and equivalents with an additional >$100 million in committed government funding, creating total available liquidity of ~$890 million.
• Operating cash flow for the first nine months was $19 million, boosted by upfront payments from Jazz and Vertex deals and litigation settlements.
• Completed a $200 million oversubscribed equity raise in Q3, ensuring sufficient liquidity to fund pipeline investments for at least the next three years.

Guidance and Future Outlook:

• Plans to initiate late-stage (Phase III) development for ABCL635 (menopausal vasomotor symptoms) in 2027 following alignment with FDA via the Model-Informed Drug Development (MIDD) program.
• 12-week washout data and Open-Label Extension (OLE) results expected in early 2027 to support dose selection and confirm efficacy durability.
• Clinical trials for ABCL635 in breast and prostate cancer-induced hot flashes are expected to initiate in 2026 (mid-stage).
• Pipeline expansion includes IND-enabling activities for ABCL992 (next-gen ABCL635) and clinical entry for ABCL688 and ABCL386 in 2027.
• Management targets transitioning the company into a late-stage clinical development entity by 2027, having successfully moved from preclinical to clinical-stage operations.

Business Segments and Product Lines:

• ABCL635: Phase II data showed a 50% placebo-adjusted reduction in hot flash frequency and 46% reduction in severity at 4 weeks; 37% of patients achieved 100% resolution (vs. 2.2% placebo). Dosing is a single 600mg injection.
• ABCL992: New next-generation half-life extended analog of ABCL635 entered IND-enabling activities; targets extended dosing intervals (potentially 1–3+ months) to improve convenience and reduce COGS.
• ABCL575: Phase I OX40L inhibitor data showed favorable PK and tolerability (65-day half-life) but development in atopic dermatitis is paused following competitor failures; no further clinical pursuit currently planned.
• New Programs: Announced ABCL385 (oncology, undisclosed indication) and ABCL646 (first-in-class ion channel antagonist), both in preclinical/IND-enabling stages with no clinical data to be disclosed until trials begin.
• Existing Pipeline: ABCL688 and ABCL386 progressing through IND-enabling activities with anticipated clinical entry in 2027.

Market and Competitive Landscape:

• ABCL635 demonstrates ~2x greater efficacy reduction in hot flash frequency compared to approved NK3R antagonists (fezolinetant and elranatant) and comparable or superior complete resolution rates to hormone therapy.
• No safety signals for gastrointestinal or liver toxicity observed with ABCL635, contrasting with adverse event profiles of oral NK3R inhibitors.
• Market interest in non-hormonal VMS treatment is surging following the removal of the hormone therapy box warning.
• Competitive positioning leverages strong differentiation in efficacy, safety (no GI toxicity), and convenience (monthly or potentially quarterly injection vs. daily pills).

Risks and Challenges:

• Reliance on future regulatory alignment for dose selection and trial design before initiating late-stage studies.
• Uncertainty regarding the durability of efficacy during the 8–12 week washout period and the translation of single-dose efficacy to multi-dose regimens.
• Risk of immunogenicity with repeat dosing, though current data shows low anti-drug antibodies (2%); monitoring ongoing in OLE.
• Potential for competitors to develop similar long-acting biologics, though ABCL992 was developed proactively to maintain market leadership.
• Clinical development failure risks in new assets (ABCL688, ABCL386, ABCL385, ABCL646) as they enter clinical testing.

Management Commentary and Tone:

• Tone was highly confident and celebratory, describing Q3 as "transformative" and a "breakthrough quarter."
• Management emphasized a successful strategic pivot from a platform company to a clinical biotech with a robust, multi-asset pipeline.
• CEO Carl Hansen highlighted the "incredible" reception from KOLs and physicians, noting strong demand to accelerate Phase III.
• CFO Andrew Booth reiterated strong liquidity and the ability to self-fund development without immediate dilution needs.

Analyst Questions and Answers:

• Clinician Feedback: Physicians reported results were "even better than hormonal therapy" and urged rapid advancement to Phase III.
• ABCL992 Strategy: Market research indicates a preference for monthly injections, with excitement for quarterly options; ABCL992 serves as a life-cycle management tool to address competitor follow-ons and broaden patient reach.
• 12-Week Data Timing: Release moved to early 2027 to allow time for finalizing Phase III design and regulatory discussions; data reflects single-dose washout to inform exposure-response modeling.
• Competitive Trials: Company has not yet confirmed inclusion of active comparators in the pivotal trial but intends to disclose details in coming months.
• New Indications: Breast cancer VMS trial design is expected to mirror existing L-enzenotant studies; prostate cancer trials require more population definition but show strong enthusiasm.
• Pipeline Prioritization: Focus remains on ABCL635; ABCL688 and ABCL386 targeted for 2027 clinical entry, while ABCL992 is on a 2028 timeline.

Other Key Points:

• ABCL575 was discontinued in the atopic dermatitis setting due to external failures of OX40L class assets (Amgen, Sanofi), though the molecule's PK/PD profile remains favorable.
• Immunogenicity data from Phase I ABCL575 showed only 2% anti-drug antibodies, providing early confidence for the platform.
• The company retains ownership of Vancouver-based lab/office buildings and a GMP facility, providing additional asset liquidity.
• Management confirmed the Phase II primary endpoint was a reduction in moderate/severe hot flashes over 4 weeks following a single 600mg dose.